Maggie Wilcox
A5103163298- Breast Cancer Treatment Studies
- Global Cancer Incidence and Screening
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Ethics in Clinical Research
- Cancer Risks and Factors
- Estrogen and related hormone effects
- Peptidase Inhibition and Analysis
- Advanced Breast Cancer Therapies
- Economic and Financial Impacts of Cancer
- Monoclonal and Polyclonal Antibodies Research
- Advances in Oncology and Radiotherapy
- Cancer Immunotherapy and Biomarkers
- Advanced Radiotherapy Techniques
- CAR-T cell therapy research
- Breast Implant and Reconstruction
- Organ Donation and Transplantation
- Gene expression and cancer classification
- Pulmonary Hypertension Research and Treatments
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- Cancer survivorship and care
- Gastric Cancer Management and Outcomes
- Patient-Provider Communication in Healthcare
The Patients Association
2013-2022
Royal Marsden Hospital
2011-2018
University of Liverpool
2018
Poole Hospital NHS Foundation Trust
2018
Royal Derby Hospital
2018
Royal Marsden NHS Foundation Trust
2018
Royal Liverpool University Hospital
2018
University Hospitals Coventry and Warwickshire NHS Trust
2017
University Hospitals Birmingham NHS Foundation Trust
2017
The Royal Wolverhampton NHS Trust
2017
Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced patient age clinicopathological factors. We hypothesise that partial-breast restricted to the vicinity of original tumour women at lower than average local will improve balance beneficial versus adverse effects compared with whole-breast radiotherapy.
BackgroundAdjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant non-inferior the 12-month regarding disease-free survival.MethodsThis study an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in UK. randomly assigned cancer,...
BackgroundPreoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It also been suggested that tumour Ki67 values after 2 weeks (Ki672W) of POAI predicts individual patient outcome better than baseline (Ki67B). The POETIC trial aimed test these two hypotheses.MethodsPOETIC was an open-label, multicentre, parallel-group, randomised, phase 3 (done 130 UK hospitals) which...
TRACERx, a prospective study of patients with primary non-small cell lung cancer, aims to map the genomic landscape cancer by tracking clonal heterogeneity and tumour evolution from diagnosis relapse.
To identify optimal chemo- and targeted therapy for women with human epidermal growth factor 2 (HER2)- negative (or unknown) advanced breast cancer.
PURPOSE CDK4/6 inhibitors are used to treat estrogen receptor (ER)–positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of palbociclib plus letrozole as neoadjuvant PATIENTS AND METHODS Postmenopausal women ER-positive primary BC and tumors greater than or equal 2.0 cm were randomly assigned 3:2:2:2 (2.5 mg/d) for 14 weeks (A); 2 weeks, then (B); (C); weeks. Palbociclib 125 mg/d was administered orally...
Abstract Murine tissues harbor signature γδ T cell compartments with profound yet differential impacts on carcinogenesis. Conversely, human tissue-resident cells are less well defined. In the present study, we show that lung a resident Vδ1 population. Moreover, demonstrate memory and effector phenotypes were enriched in tumors compared nontumor tissues. Intratumoral possessed stem-like features skewed toward cytolysis helper type 1 function, akin to intratumoral natural killer CD8 +...
The preoperative setting is increasingly popular for the clinical investigation of hormonal agents and new biological drugs. effectiveness endocrine well established estrogen receptor–positive disease, emphasis in studies on their combination with targeted at resistance mechanisms over 3 or more months. New are also being assessed early evidence efficacy shorter-term window-of-opportunity studies. establishment Ki67 as an intermediate marker treatment benefit long-term outcome, drugs,...
Abstract Background Experimental evidence (Fisher et al, 1989) & a small clinical trial (IMPACT) respectively suggested peri-operative endocrine therapy (ET) may improve long-term disease-related outcome in patients undergoing primary surgery for ER positive (ER+) breast cancer (BC) that tumor Ki67 levels after 2 weeks of aromatase inhibitor (POAI) might offer an effective way predicting the need additional adjuvant treatment. POETIC (*Peri-Operative Endocrine Therapy - Individualising...
Abstract Background The LOw RISk DCIS (LORIS) study was set up to compare conventional surgical treatment with active monitoring in women ductal carcinoma situ (DCIS). Recruitment trials a surveillance arm is known be challenging, so strategies maximise patient recruitment, aimed at both patients and recruiting centres, were implemented. Methods Women aged ≥ 46 years histologically confirmed diagnosis of non-high-grade eligible for 1:1 randomisation either surgery or monitoring. Prior...
Background The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable breast cancer. Twelve months’ trastuzumab, tested in registration trials, was adopted as standard treatment 2006. Subsequently, similar were demonstrated using 9 weeks trastuzumab. Shorter durations therefore non-inferiority. Objectives To establish whether or not 6 is non-inferior 12 the...
Breast cancer is a diverse and varied disease. Recent research has shown that the collection of multiple biopsies before surgery can help researchers determine how responding to treatment predict for long-term outcomes. However be uncomfortable, sometimes clinicians teams in hospitals may reluctant offer clinical trials requiring several patients who have been recently diagnosed with breast cancer. The Institute Cancer Research Clinical Trials Statistics Unit (ICR-CTSU) oversees large number...
1570 Background: The degree of over-diagnosis and over-treatment for ductal carcinoma in situ (DCIS) remains contentious. Hypotheses from retrospective data were tested a prospective, population-based study. Methods: A prospective longitudinal cohort 12,838 women diagnosed through national breast screening program accrued 2003-2012 with proforma imaging, surgery, pathology adjuvant therapy. Follow-up was linked to databases case note review analyse patterns care, recurrence mortality....